BLUE GENES NEWS

All News

All News Press Releases PGX Center
Tru-1 By BlueGenes Launches to Advance Precision Health Through Smarter Genetic Insights

Tru-1 By BlueGenes Launches to Advance Precision Health Through Smarter Genetic Insights

May 21, 2026 • Press Releases

TRU-1 by Blue Genes has officially launched, introducing a new approach to precision wellness through genetic insight. The platform is designed to help provide additional visibility into how individuals may respond differently to wellness strategies, supplements, and GLP-1 related programs based on their genetics.
Blue Genes Successfully Completes SOC 2 Audit

Blue Genes Successfully Completes SOC 2 Audit

January 19, 2026 • Press Releases

Phoenix, AZ, January 16, 2026 — Blue Genes (https://bluegeneslab.com), a personalized medicine company focused on pharmacogenetic (PGx) testing and genetic insights to support safer, more effective medication decisions, today announced the successful completion of its SOC 2 Type II examination as of January 16, 2025.

 BlueGenesLab Expands Genetic Panel to Include Three New GLP-1–Related Genes

BlueGenesLab Expands Genetic Panel to Include Three New GLP-1–Related Genes

September 08, 2025 • Press Releases

SCOTTSDALE, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- BlueGenesLab, a precision genomics company headquartered in Scottsdale, Arizona, today announced the addition of three genes to its clinical testing panel that influence GLP‑1 (glucagon‑like peptide‑1) biology. The expanded panel aims to improve personalized treatment strategies for metabolic conditions such as type 2 diabetes, obesity, and related cardiometabolic risks by providing clinicians and patients with a deeper genetic view of pathways that regulate GLP‑1 signaling, secretion, and response.

Latest News

BlueGenes and Levrx Partner to Integrate Real-Time Genetic Insights into the Pharmacy Benefit Experience

BlueGenes and Levrx Partner to Integrate Real-Time Genetic Insights into the Pharmacy Benefit Experience

June 19, 2025 • Press Releases

SCOTTSDALE, Ariz., June 16, 2025 (GLOBE NEWSWIRE) -- BlueGenes, a leading pharmacogenetics (PGX) solution, and Levrx Technology, a digital pharmacy engagement platform, have announced a strategic partnership. Together they aim to accelerate the adoption of personalized prescribing by seamlessly integrating genetic testing insights into pharmacy benefit systems.
BlueGenes Partners with Level Care to Revolutionize Medication Management for Union Members

BlueGenes Partners with Level Care to Revolutionize Medication Management for Union Members

April 21, 2025 • Press Releases

SCOTTSDALE, AZ – BlueGenes, a pioneering technology company specializing in precision medicine, today announced a strategic partnership with Level Care, the healthcare division of the carpenters union. This collaboration will provide Level Care members with access to BlueGenes' cutting-edge pharmacogenomic (PGX) testing, ensuring safer and more effective medication management.
Minimizing the Guessing Game in Pain Management

Minimizing the Guessing Game in Pain Management

May 08, 2024 • PGX Center

A New Study Brings Pharmacogenetics to Postoperative Care Patients preparing to undergo surgery face many unknowns. Will the surgery improve their quality of life? How long will they take to recover? Many are concerned about the pain and discomfort surrounding the surgery. What they may not be considering is how their body will respond to pain medication(s) prescribed during and after surgery.
A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care

A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care

May 08, 2024 • PGX Center

Adverse drug reactions (ADRs) are a significant public health concern and a leading cause of hospitalization; they are estimated to be the fourth leading cause of death and increasing healthcare costs worldwide. Carrying a genetic variant could alter the efficacy and increase the risk of ADRs associated with a drug in a target population for commonly prescribed drugs.
© 2026 Blue Genes - Pharmacogenetics (PGX) Testing Kits | Privacy Policy | Terms of Use | SMS Help